Top Pharmaceutical Companies in Los Angeles, CA (79)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Newer businesses such as Pharma Direct and subscriptions are expanding rapidly, with clear momentum highlighted in 2026. Investment is being shifted toward these lines to replace slower legacy revenue.
Future-Ready Strategy: Management is prioritizing Pharma Direct and subscription products and raised 2026 revenue guidance, signaling a transition aimed at restoring overall growth. These segments are described as the main engines expected to offset declines in the legacy business.
Profitability: Profitability remains solid even as the top line fluctuates, including positive GAAP earnings and substantial adjusted EBITDA in Q2 2026. Operating cash flow also strengthened, supporting continued execution.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Caprion Biosciences was a leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry, specializing in advanced immunology and proteomics services. It has since rebranded to CellCarta, a global contract research organization.
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
Tarsus is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs.
Lightship is your complete solution for decentralized clinical trials. We built our virtual-first clinical trial model from the ground up, allowing patients to participate in clinical trials from the comfort of home. Come join the team perfecting the way clinical trials are done!
.jpg)
PDC Pharmacy is a long-term care pharmacy that provides specialized pharmaceutical services for individuals with intellectual disabilities, autism, and behavioral health needs, exclusively serving provider agencies.
Sinclair is a global medical aesthetics company that specializes in manufacturing and commercializing a wide portfolio of injectable and EBD treatments to support a consumer's full aesthetic journey. As a wholly owned subsidiary of Huadong Medicine Company Limited, the company's products are available in more than 55 countries through a direct presence in key global markets and a network of...
Sinclair's Top Stability & Growth Strengths
Strong Market Position & Advantage: Sinclair is positioned as a top-tier U.S. broadcaster with one of the largest station portfolios and owned networks that extend national reach. It is widely characterized as a leading player in local TV and sports content, even as Nexstar holds the top spot.
Strong Revenue Growth: Recent 2026 quarters show year-over-year revenue gains and higher full-year guidance, supported by stronger political demand, improving local media trends, and stable distribution. Digital-led core advertising is noted as a contributor to the uptick.
Innovation-Driven Growth: The company plays a leading role in ATSC 3.0/NextGen TV through ONE Media and continues to build specialty assets such as Tennis Channel. These initiatives broaden technology and content platforms that can diversify growth beyond legacy broadcast.
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with...
Chinn Urology was founded primarily to serve as an aid towards prescription patients of all types and skill levels. While Chinn Urology is ever-expanding, our goal is always to provide patients with accurate, relevant medical guides, articles and more.
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
Seragon is a research-based biopharmaceutical company, committed to innovating cutting-edge discoveries in biotechnology and medicine.
Anton Paar develops, produces, distributes and provides support for analytical instruments used in research, development and quality control worldwide. Ever since Mr. Anton Paar founded his one-man workshop in 1922, the Austrian based company has continuously found new ways to merge high-precision engineering with scientific curiosity. The company currently has more than 3500 employees and is active in over 170...
ICU Medical connects patients and caregivers through safe, life-saving, life-enhancing IV therapy systems, software, solutions, and consumables.
Lief Labs is a premier formulation and product development innovator and contract manufacturer specializing in dietary supplements and nutraceuticals. Based in Valencia, California, the company provides turn-key solutions for brands in the vitamins and minerals space, offering full-service manufacturing of products such as powders, tablets, and capsules to help clients build premium, lasting, and innovative brands.
Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970, specializing in R&D, manufacturing, distribution, marketing, and sales of pharmaceutical products, cosmetics, and food supplements.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have...
U.S. Dermatology Partners is one of the largest physician-owned dermatology practices in the United States, providing premier medical, surgical, and cosmetic skin care to over two million patients annually. With more than 130 locations across nine states, the organization focuses on patient-first care, combining the personalized experience of private practice with a coordinated network of specialized physicians and national thought...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
Lundbeck's Top Stability & Growth Strengths
Strong Revenue Growth: Feedback suggests total revenue increased at constant exchange rates across 2025 and into H1 2026, with double-digit gains in the U.S. and Europe supporting momentum.
Profitability: Earnings are considered to have scaled alongside revenue, with adjusted EBITDA rising materially, indicating improved profit leverage.
Product Line Growth: Strategic brands such as Vyepti and Rexulti are often cited as the primary engines of expansion, showing strong double-digit growth and contributing the majority of total revenue.
